medrogestone and Hypogonadism

medrogestone has been researched along with Hypogonadism* in 1 studies

Other Studies

1 other study(ies) available for medrogestone and Hypogonadism

Article	Year
[Bone density before and after the hormonal therapy of young women with hypergonadotropic hypogonadal amenorrhea]. Deutsche medizinische Wochenschrift (1946), 1992, Feb-21, Volume: 117, Issue:8 Dual energy X-ray absorptiometry of bone density in the lumbar vertebral column was performed in 32 young women (mean age 24.6 [19-34] years) with hypergonadotropic hypogonadal amenorrhoea. There was a significantly lower bone density (0.74 +/- 0.27 g/cm2) than in a control group of 27 women of similar age (1.17 +/- 0.081 g/cm2; P less than 0.001). Subsequently 21 of the 32 women received cyclical hormone substitution therapy for 24 months (day 1-30: 0.625 mg conjugated oestrogens; additionally, on days 20-30: 5 mg medrogestone; followed by a seven-day pause). After 6 months bone density, compared with that of the 11 untreated women, had increased significantly (P less than 0.001). It is therefore recommended that young hypoestrogenemic women should receive early and continuous hormone substitution treatment. Topics: Absorptiometry, Photon; Adult; Amenorrhea; Bone Density; Drug Therapy, Combination; Estradiol; Estradiol Congeners; Female; Follicle Stimulating Hormone; Humans; Hypogonadism; Luteinizing Hormone; Medrogestone; Time Factors	1992

Article

Year

[Bone density before and after the hormonal therapy of young women with hypergonadotropic hypogonadal amenorrhea].

Deutsche medizinische Wochenschrift (1946), 1992, Feb-21, Volume: 117, Issue:8

Dual energy X-ray absorptiometry of bone density in the lumbar vertebral column was performed in 32 young women (mean age 24.6 [19-34] years) with hypergonadotropic hypogonadal amenorrhoea. There was a significantly lower bone density (0.74 +/- 0.27 g/cm2) than in a control group of 27 women of similar age (1.17 +/- 0.081 g/cm2; P less than 0.001). Subsequently 21 of the 32 women received cyclical hormone substitution therapy for 24 months (day 1-30: 0.625 mg conjugated oestrogens; additionally, on days 20-30: 5 mg medrogestone; followed by a seven-day pause). After 6 months bone density, compared with that of the 11 untreated women, had increased significantly (P less than 0.001). It is therefore recommended that young hypoestrogenemic women should receive early and continuous hormone substitution treatment.

Topics: Absorptiometry, Photon; Adult; Amenorrhea; Bone Density; Drug Therapy, Combination; Estradiol; Estradiol Congeners; Female; Follicle Stimulating Hormone; Humans; Hypogonadism; Luteinizing Hormone; Medrogestone; Time Factors

1992